Impact of Secukinumab on Endothelial Dysfunction and Other Cardiovascular Disease Parameters in Psoriasis Patients Over 52 Weeks

Journal of Investigative Dermatology - United Kingdom
doi 10.1016/j.jid.2018.10.042
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Endothelial Dysfunction and Cardiovascular Disease

2007English

Drug Survival of Secukinumab in Real-World Plaque Psoriasis Patients: A 52-Week, Multicenter, Retrospective Study

Journal of the American Academy of Dermatology
Dermatology
2018English

Role of Endothelial Dysfunction in Cardiovascular Disease: A Review

Journal of the University of Malaya Medical Centre
Medicine
2000English

Advanced Peripheral Microvascular Endothelial Dysfunction and Polyvascular Disease in Patients With High Cardiovascular Risk

Journal of Cardiology
Cardiovascular MedicineCardiology
2016English

Endothelial Dysfunction in Patients With Buerger Disease

Vascular Health and Risk Management
2017English

Adalimumab for Nail Psoriasis: Efficacy and Safety Over 52 Weeks From a Phase‐3, Randomized, Placebo‐Controlled Trial

Journal of the European Academy of Dermatology and Venereology
DermatologyInfectious Diseases
2019English

Effect of Correction of Endothelial Dysfunction on Clinical and Immunological Parameters in Patients With Bronchial Asthma

International Journal of Radiology & Radiation Therapy
2018English

Dyshidrotic Eczema in Two Patients on Secukinumab for Plaque Psoriasis: A Case Report

SAGE Open Medical Case Reports
2020English

Non-Invasive Measurements to Stratify Cardiovascular Disease Risk in Psoriasis Patients

2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy